Lv3
220 积分 2022-05-26 加入
Anlotinib plus chemoradiotherapy in the treatment for FIGO stage IB3 and IIB-IVA cervical cancer: A prospective single-arm, single-center, exploratory phase II trial (299)
2天前
已完结
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
15天前
已完结
Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
26天前
已完结
Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature
26天前
已关闭
Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study
1个月前
已完结
Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases
1个月前
已完结
肾癌靶向治疗与免疫治疗临床研究前沿
1个月前
已完结
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
1个月前
已完结
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
1个月前
已完结
皖公网安备34019202002308
